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a b s t r a c t
Functional disorders of T lymphocytes play an essential role in abnormal immune res-
ponse in patients with chronic lymphocytic leukemia. The aim of this study was to
assess the profile of cytokines expressed by T cells derived from patients with CLL. We
have demonstrated that the intracellular levels of IL-2, IL-4, IFN-g, TNF, IL-6 and IL-10
were significantly higher in T cells of CLL patients than in healthy donors. Moreover, the
percentages of CD4+/CD3+/TNF+, CD4+/CD3+/IFN-g+, and CD4+/CD3+/IL-2+ cells were sig-
nificantly higher in ZAP-70-positive patients compared with ZAP-70-negative ones. Like-
wise, significantly higher percentages of CD4+/CD3+/TNF+, CD4+/CD3+/IFN-g+ cells were
observed in CD38-positive than in CD38-negative cases. What is more, there was
a significant difference in median percentage of CD3+/CD4+ cells expressing TNF, IL-4,
IFN-g, IL-2 or IL-6 between patients carrying the 11q22.3 deletion and/or the 17p13.1
deletion and patients without these genetic aberrations. Our results confirm the functio-
nal disorders of T cells in CLL and their influence on the clinical course of the disease.
© 2013 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i
Transfuzjologii. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Chronic lymphocytic leukemia (CLL) is the most common
type of leukemia of adults in the Western World. It is
characterized by a heterogenous clinical course with survi-
val ranging from months to several years [1, 2]. In many
cases patients do not have any symptoms for at least a few* Corresponding author at: ul. Chodźki 4a, 20-093 Lublin, Poland. Tel.: 
E-mail address: mpieczykolan@vp.pl (M. Pieczykolan).
0001-5814/$ – see front matter © 2013 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut H
http://dx.doi.org/10.1016/j.achaem.2013.07.002years and the disease is diagnosed during periodical routine
laboratory tests. Generally, two schemes of the disease
course are adopted: the first is slow and infrequently
requires treatment, while the other is fast-growing, with
poor prognosis and short survival [3]. The available treat-
ments can often lead to the remission of the disease, but
most patients have relapses, which implies that the CLL still
remains an incurable disease.+48 81 75 64 854; fax: +48 81 75 64 840.
ematologii i Transfuzjologii. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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sive proliferation and accumulation of the long-lived mor-
phologically mature but immunologically incompetent
malignant-altered B lymphocytes, in blood, bone marrow
and peripheral lymphoid organs [1]. The clinical diagnosis of
CLL requires an assessment of monoclonal B-cell population
in peripheral blood with a minimum threshold of more than
5000 cells/ml [4]. A typical phenotype characteristic of leuke-
mic cells is a co-expression of B lymphocyte antigens (CD19,
CD20, CD23) and T cell marker CD5 [5–7].
In chronic lymphocytic leukemia there are many immu-
nological disorders of both the humoral and the cellular
immune response that are considered to be involved in
disease pathogenesis.
Numerous observations indicate that the long-lived in vivo
CLL cells quickly undergo spontaneous apoptosis when they
are cultured in vitro [8]. This suggests that in vivo, factors like
cytokines significantly affect the activation, proliferation and
extended survival [9–11]. Therefore, in this study we have
focused on the assessment of cytokines secreted by T cells
with a growth-promoting potential, including: tumor necrosis
factor (TNF) [12–14], interleukin 2 (IL-2) [15], interleukin 6 (IL-
6) [16–18], interferon IFN-g and interleukin 4 (IL-4) and play
a role in the interactions between tumor cells and immune
effector cells [19]. Moreover, we analyzed intracellular expres-
sion of IL-10 which was found to be associated with CLL
progression [20] and IL-12 was considered as an important
element of anti-tumor response as well [21].
Patients
Fifty-five newly diagnosed and previously untreated, con-
secutive, patients with CLL were enrolled for this study. The
diagnosis of CLL was made on the basis of NCI-WG criteria
[22]. There were 21 women and 34 men, with the median
age of 66 years (range 40–83). At the time of diagnosis,
patients were staged according to the Rai staging system as
follows: stage 0–21 cases, stage 1–15 cases, stage 2–12 cases,
stage 3–4 cases and stage 4–3 case. Cytogenetic analysis at
the time of testing was available for 36 out of the 55 study
patients. The patients were assigned to two groups accord-
ing to this analysis. The first group consisted of 11 patients
who had 11q22.3 deletion and/or 17p13.1 deletion. The
second group consisted of the remaining 25 patients with-
out these unfavorable cytogenetic abnormalities.
Control group consisted of 10 age-matched healthy volun-
teers (HV). The Local Ethical Committee approved the proto-
col of the study and all the patients signed informed consent.
Monoclonal antibodies and other reagents
The following fluorochrome-conjugated monoclonal antibo-
dies (MoAbs) were used for the detection of intracellular
cytokines: IL-12 PE, IL-2 PE, IL-4 PE, TNF PE, IFN-g PE, IL-10 PE
and IL-6 PE (Becton Dickinson, USA). For the identification of
cell surface antigens the following antibodies were used: anti-
CD3 PerCP, anti-CD4 FITC, (BD, USA). The IgG 1 FITC PE PerCP
– conjugate mouse mAbs from Becton Dickinson was used as
a negative control. Phorbol 12-mysistate 13-acetate (PMA),
ionomycin and brefeldin A (BFA) were purchased from Sigma.Cell preparation and in vitro stimulation of T cells
All the peripheral blood samples were collected into hepar-
inized tubes and immediately processed. Mononuclear cells
were isolated by the density gradient centrifugation on Gra-
disol L (Aqua Medica, Poland). Interphase cells were removed
and washed twice in phosphate-buffered saline (PBS). Cells
from every sample were cultured in a complete culture
medium (RPMI 1640 supplemented with fetal calf serum
100 IU mL1 penicillin, 100 mg mL1 streptomycin) for 4 h. The
cells were stimulated with a mixture containing phorbol
myristate acetate (PMA, 25 ng/ml), ionomycin (1 mg/ml). Cyto-
kine secretion was blocked with brefeldin (10 mg/ml). The
incubators were set at 37 8C in a 5% CO2 environment. More-
over, this procedure was also performed on non-activated
lymphocytes using only brefeldin A in order to assess the level
of residual cytokine synthesis from in vitro activation.
Surface and intracellular staining
For surface staining, cultured PBMCs were washed twice in
PBS and then incubated with appropriate MoAbs specific for
CD3 and CD4 for 30 min at 4 8C. After surface staining, the
cells were washed, subsequently fixed and permeabilized
with BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD
Biosciences). Afterwards, the cells were incubated with an
appropriate amount of MoAbs for intracellular cytokine
staining (20 min at 4 8C in the dark). The cells were then
washed twice with PBS, and analyzed by flow cytometry.
Flow cytometric analysis
The samples were analyzed by flow cytometry using
a Becton Dickinson FACSCalibur instrument. Five data para-
meters were assessed: linear forward and side scatter (FSC,
SSC), FL-1(FITC), FL-2(PE) and FL-3 (PerCP). An acquisition
gate was established on their forward and side light scatter
properties (R1 region), which included mononuclear cells
and excluded dead cells and debris (Fig. 1). The R1 gated
events were analyzed for CD3 positive cells (R2). The final
dot plots, using R1 and R2 regions, represent the percentage
of CD3+/CD4+ cells expressing cytoplasmic cytokines.
For each analysis, 10,000 events were acquired and
analyzed using CellQuest Pro software. Isotype-matched
antibodies were used to verify the staining specificity and as
a guide for setting the markers to delineate positive and
negative populations.
Flow cytometric analysis of CD38 and ZAP-70 expression in
CLL cells
CLL cells were stained for CD38 antigen and ZAP-70 protein
expression (as described previously [23]). The cut-off point
for CD38 or ZAP-70 positivity in leukemic cells was 20%.
Statistical analysis
The Mann–Whitney U test was applied for statistical com-
parison of the results between CLL patients and HV, as well
as between CLL patients in different stages of the disease.
Fig. 1 – The dot plot shows representative date from one CLL patient, illustrating the analysis method for identification of
CD4+ T cells expressing appropriately cytokines following three-color staining. (a) The dot plot shows the forward scatter/
side scatter (FSC/SSC) distribution and the gate (region R1) used to select lymphocytes for analysis. (b) The R1 gate events
were then analyzed for CD3 positive cells (CD3+) were gated (region R2). The dot plot shows the SSC vs. CD3PerCP
distribution. (c) The final dot plot CD4FITC vs. IFN PE, was established by combined gating of events using R1and R2. The
number in the upper right quadrant on the dot plot represents the percentage of CD3+/CD4+ cells expressing cytoplasmic IFN
Ryc. 1 – Przykładowy obraz z cytometru przepływowego, przedstawiający metodę analizy komórek T CD4+ wykazujących ekspresję
cytokin. (a) Obraz przedstawiający rozkład komórek w zależność od wielkości i ziarnistości (FSC/SSC), region R1 zawiera limfocyty.
(b) Z regionu R1 wyodrębniono komórki CD3-pozytywne i oznaczono je jako R2. Obraz przedstawia zależność SSC od CD3PerCP. (c)
Końcowy obraz, przedstawiający procent komórek CD3+/CD4+ wykazujących ekspresję IFN-g, zawiera komórki z rejonów R1 i R2.
Komórki w górnym prawym rogu, reprezentują odsetek limfocytów CD3+/CD4+ z cytoplazmatyczną ekspresją IFN-g
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Windows. Differences were considered statistically signifi-
cant with a p-value 0.05.
Results
We measured the intracellular cytokines expression of IL-2,
IL-4, IFN-g, TNF, IL-6, IL-10 and IL-12 in T cells of patientsFig. 2 – Intracellular IL-2 expression in CD3+/CD4+ cells from on
without stimulation (a), and with PMA and ionomycin stimulati
Ryc. 2 – Przykładowy obraz przedstawiający odsetek komórek CD3+
przed (a) i po stymulacji PMA i jonomycyną (b)with CLL and healthy control group. Representative FACS
profiles showing intracellular staining of spontaneous and
in vitro activated cells are showed in Fig. 2. In CLL patients
as well as in healthy control, the percentage of CD4+/CD3+
cells with intracellular cytokine expression in non-activation
assays was frequently lower than 1%, comparable with the
level of autofluorescence.
The mean percentages of CD3+CD4+ cell positive for IL-2,
IL-4, IFN-g, TNF, IL-6 and IL-10 were significantly higher ine representative CLL patent. Expression of intracellular IL-2
on (b)
/CD4+ z wewnątrzkomórkową ekspresją IL-2. Ekspresja IL-2
Table I – Median percentage of CD3+CD4+ cells with
intracellular TNF, IFN-g, IL-4, IL-6, IL-2, IL-12 and IL-10
expression in peripheral blood from CLL patients and
healthy control
Tabela I – Średni odsetek limfocytów CD3+CD4+ z we-
wnątrzkomórkową ekspresją TNF, IFN-g, IL-4, IL-6, IL-2,
IL-12 i IL-10 w krwi obwodowej pacjentów z PBL i zdrowych
dawców
Variable CLL Healthy control p-Value
CD3+CD4+TNF+ 15.17 5.46 0.003
CD3+CD4+IFN-g+ 6.70 4.24 0.002
CD3+CD4+IL-4+ 1.46 0.68 0.001
CD3+CD4+IL-10+ 1.06 0.88 0.009
CD3+CD4+IL-6+ 0.86 0.47 0.001
CD3+CD4+IL-2+ 13.85 8.41 0.036
CD3+CD4+IL-12+ 1.30 2.24 0.167
The p-value was calculated using the U Mann–Whitney test ( p-
value of <0.05 was considered statistically significant).
Wartość p obliczono, stosując test U Manna–Whitneya ( p < 0.05
uznano za istotne statystycznie).
Table III – Median percentage of CD3+CD4+ cells with
intracellular TNF, IFN-g, IL-4, IL-6, IL-2, IL-12 and IL-10
expression in peripheral blood from CLL patients with
different ZAP-70 and CD38 antigen expressions
Tabela III – Średni odsetek komórek CD3+CD4+ z wewnątrz-
komórkową ekspresją TNF, IFN-g, IL-4, IL-6, IL-2, IL-12 i IL-
10 w krwi obwodowej pacjentów z PBL wykazujących różną






CD3+CD4+TNF+ 43.14 51.55 0.01
CD3+CD4+IFN-g+ 16.33 22.28 0.02
CD3+CD4+IL-4+ 3.28 3.11 0.14
CD3+CD4+IL-10+ 1.55 1.57 0.49
CD3+CD4+IL-6+ 1.80 1.01 0.61
CD3+CD4+IL-2+ 17.01 26.08 0.01






CD3+CD4+TNF+ 40.05 49.68 0.014
CD3+CD4+IFN-g+ 16.00 19.40 0.035
CD3+CD4+IL-4+ 3.45 2.78 0.16
CD3+CD4+IL-10+ 1.55 1.58 0.27
CD3+CD4+IL-6+ 17.39 20.59 0.052
CD3+CD4+IL-2+ 1.08 1.02 0.43
CD3+CD4+IL-12+ 1.39 1.94 0.067
The p-value was calculated using the U Mann–Whitney test ( p-
value of <0.05 was considered statistically significant).
Wartość p obliczono, stosując test U Manna–Whitneya ( p < 0.05
uznano za istotne statystycznie).
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However, no significant differences were observed between
these groups in the percentage of CD3+CD4+ cells expres-
sing IL-12.
The low-risk group (Rai stage 0) and the intermediate-
risk group (Rai stages I and II) CLL patients expressed
statistically significant higher levels of IL-4, IFN, TNF, IL-6
and IL-10 than healthy individuals ( p < 0.05). Moreover, CLL
patients in the Rai stages 0-II showed a higher mean
expression of IL-10 and IL-6 when compared to the group of
patients in more advanced stages of the disease (III–IV)
(Table II). However, these differences were not statistically
significant.
In our study, the percentages of CD4+/CD3+/TNF+, CD4+/
CD3+/IFN-g+, and CD4+/CD3+/IL-2+ cells were significantly
higher in ZAP-70-positive patients compared with ZAP-70-
negative patients (Table III). Likewise, significantly higher
percentages of CD4+/CD3+/TNF+, CD4+/CD3+/IFN-g+ cells
were observed in CD38-positive than in CD38-negative
patients (Table III).
Cytogenetic analysis at the time of testing was available
for 46 out of the 55 study patients. There was a significantTable II – Median percentage of CD3+CD4+ cells with
intracellular TNF, IFN-g, IL-4, IL-6, IL-2, IL-12 and IL-10
expression in peripheral blood from CLL patients in
different stages of disease
Tabela II – Średni odsetek limfocytów CD3+CD4+ z we-
wnątrzkomórkową ekspresją TNF, IFN-g, IL-4, IL-6, IL-2,
IL-12 i IL-10 w krwi obwodowej pacjentów z PBL w różnych
stadiach zaawansowania choroby
Variable 0 I–II III–IV
CD3+CD4+TNF+ 15.78 11.55 21.10
CD3+CD4+IFN-g+ 6.70 6.54 9.28
CD3+CD4+IL-4+ 1.48 1.43 3.16
CD3+CD4+IL-10+ 1.07 1.04 1.00
CD3+CD4+IL-6+ 0.86 0.87 0.45
CD3+CD4+IL-2+ 12.63 13.88 23.99
CD3+CD4+IL-12+ 1.47 1.02 NEdifference in median percentage of CD3+/CD4+ cells expres-
sing TNF, IL-4, IFN-g, IL-2 or IL-6 between patients carrying
the 11q22.3 deletion and/or the 17p13.1 deletion and
patients without these genetic aberrations (Table IV). There
were no significant differences in CD3+/CD4+/IL-10+ and
CD3+/CD4+/IL-12+ cell percentages between patients with del
(11q22.3) or/and del(17p13.1) and patients without these
unfavorable genetic aberrations (Table IV). Additionally, the
percentage of T lymphocytes expressing all analyzed cyto-
kines was higher in the patient with del(17p13.1) than in the
patients with del(11q22.3) (Table V). However, these differ-
ences were not statistically significant.
Discussion
For many years, the main function in anticancer response
was attributed to cytotoxic T lymphocytes (CD8+, Tc). Nowa-
days it is known that T helper lymphocytes (CD4+, Th) play
an essential role in the regulation of cell mediated anti-
tumor responses while their respective populations may
inhibit or promote tumor growth through the cytokine
secretion profile. In this study, we have undertaken the
assessment of the functional T helper cell function in
patients with chronic lymphocytic leukemia, by evaluating
their cytokine secretion.
We have measured the intracellular expression of
selected cytokines in CLL cells, demonstrating that the
levels of IL-2, IL-4, IFN-g, TNF, IL-6 and IL-10 after in vitro
Table IV – Median percentage of CD3+CD4+ cells with
intracellular TNF, IFN-g, IL-4, IL-6, IL-2, IL-12 and IL-10
expression in peripheral blood from CLL patients sub-
divided according to cytogenetic analysis
Tabela IV – Średni odsetek limfocytów CD3+CD4+ z we-
wnątrzkomórkową ekspresją TNF, IFN-g, IL-4, IL-6, IL-2,
IL-12 i IL-10 w krwi obwodowej pacjentów z PBL, podzielo-











CD3+CD4+TNF+ 56.38 44.16 0.01
CD3+CD4+IFN-g+ 31.12 11.10 0.0004
CD3+CD4+IL-4+ 5.71 2.52 0.001
CD3+CD4+IL-10+ 1.50 1.52 0.60
CD3+CD4+IL-6+ 2.61 0.92 0.002
CD3+CD4+IL-2+ 29.61 17.17 0.03
CD3+CD4+IL-12+ 0.25 1.79 0.43
The p-value was calculated using the U Mann–Whitney test ( p-
value of <0.05 was considered statistically significant).
Wartość p obliczono, stosując test U Manna-Whitneya ( p < 0.05
uznano za istotne statystycznie).
Table V – Median percentage of CD3+CD4+ cells with
intracellular TNF, IFN-g, IL-4, IL-6, IL-2, IL-12 and IL-10
expression in peripheral blood from CLL patients with del
(11q22.3) and del(17p13.1)
Tabela V – Średni odsetek limfocytów CD3+CD4+ z we-
wnątrzkomórkową ekspresją TNF, IFN-g, IL-4, IL-6, IL-2,
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cells. Our results suggest that the production of studied
cytokines by T cells may play a role in the maintenance of
leukemic cells survival and proliferation.
We have also found significantly higher intracellular IL-2
expression in CD3+/CD4+ T cells from CLL patients than in
healthy individuals, which confirms earlier results of Rooss-
manns et al. who showed a significantly higher level of
spontaneous production of IL-2 in patients with leukemia as
compared to the control group [24]. In contrast, other
investigators such as Gallego et al. detected a significantly
lower percentage of CD4+ cells expressing IL-2 after activa-
tion with PMA and ionomycin in CLL patients as compared
to the control group [25]. The authors confirm the results by
the ELISA test. Furthermore, in contrast to the results of the
presented study, they found no differences in the level ofintracellular cytokines such as TNF and IFN between the
study and the control group. These discrepancies might
result from the different methods used for the analysis of
cytokines expression as well as the heterogeneity of the
disease.
In our study we have found no correlation between the
stage of the disease and the level of cytokines secreted by
T cells. Different results were presented by Hulkkonen et al.
[26], who showed variations in the secretion of TNF and
IL-6, depending on the stage of the disease. The level of
secreted cytokines after stimulation with PMA was signifi-
cantly lower in the more advanced stages of the disease,
according to Binet's classification.
Currently there is a general consensus that the expres-
sion of ZAP-70 protein and CD38 antigen by leukemic cells
belongs to the important prognostic markers in CLL. In our
study, the higher percentage of T cells expressing TNF, IFN-
g and IL-2 in the ZAP-70+ and CD38+ in comparison to ZAP-
70– and CD38- group indicates that the production of
cytokines is significantly connected with the clinical course
of disease; the more aggressive ZAP-70+ or CD38+ CLL cases
are characterized by a higher capability for the production
of cytokines responsible for disease pathogenesis. What is
more, the intracellular cytokine expressions were signifi-
cantly higher in patients with high-risk cytogenetic aberra-
tions such as deletion of 17p or 11q. Apart from providing
insights into the pathogenesis, genomic aberrations identify
subgroups of patients with distinct clinical pictures: lym-
phadenopathy (11q deletion) or resistance to therapy (17p
deletion). Deletions at 11q and particularly 17p are asso-
ciated with rapid disease progression or inferior survival
[27]. Genomic aberrations (i.e., 11q and 17p deletion) help to
define biological and clinical subgroups. In our study the
intracellular cytokine expressions were higher in patients
with del(11q22.3) or/and del(17p13.1) than in patients with-
out these unfavorable genetic aberrations. Deletions of 17p
and 11q have been associated with unfavorable prognosis.
Nevertheless, the deletion of 17p was described as the
strongest independent predictor for aggressive behavior,
resistance to chemotherapy and early death [27]. In our
study we observed a higher intracellular cytokine expression
in patients with 17p deletion than in patients with 11q
deletion. However, this difference was not statistically
significant. In our study the cytogenetic analysis at the time
of testing was available for 36 out of the 55 study patients.
It should be noted that the group of patients with 11q22.3
deletion or 17p13.1 deletion had only 6 and 5 patients,
respectively. We can suppose that future analysis is
required in more numerous groups of patients.
CLL patients show much lower percentages of circulating
T-lymphocytes than it is observed in normal peripheral
blood samples [28]. Although the relative percentage of
T cells in the peripheral blood is decreased, the absolute
number is frequently increased. Our data suggest that it is
very likely that malignant cells, whose number is extremely
high in the blood of patients with leukemia, regulate the
production of cytokines by T lymphocytes.
In summary, the possible large impairment of
T lymphocyte function in the later stages, as compared to
the early stages of the disease, may affect cytokine secretion
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